Leonard Klein
Hematology & Oncology · Niles, ILNPI 1255328878
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $919 of the $1,490 with a category attached, or 61.7%. 19 manufacturers reported payments, led by Pfizer at 34.1% of the total. Reporting peaked in 2019 at $589 and has fallen 95.8% since, to $25 in 2024. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 52 payments — averaging $28.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$508
- Novartis$173
- Boston Scientific$140
- Lilly USA, LLC$126
- Astellas Pharma US Inc$99
- Pharmacyclics LLC, An Abbvie Company$71
- plus $373 from 13 others
Across 524 payments — averaging $3678.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$746K
- Incyte Corporation$133K
- Seagen Inc.$128K
- TG Therapeutics, Inc.$95K
- AbbVie$89K
- Genentech, Inc.$89K
- plus $648K from 17 others
What the payments were for
- Speaking & faculty fees$33022%
- Food & beverage$91962%
- Education$24116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $508 |
| Novartis | 10 | $173 |
| Boston Scientific | 2 | $140 |
| Lilly USA, LLC | 2 | $126 |
| Astellas Pharma US Inc | 1 | $99 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $71 |
| Johnson & Johnson(2 entities) | 4 | $65 |
| Bristol Myers Squibb | 3 | $51 |
| ADC Therapeutics America, Inc. | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Deciphera Pharmaceuticals Inc. | 1 | $28 |
| AstraZeneca | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Epizyme, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Amgen | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Merck | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,490 in reported general payments places this provider in the 45th percentile of 580 hematology & oncology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 26 | $1,470 |
| Letrozole | 12 | $200 |
| Metoprolol Succinate | 13 | $147 |
| Rosuvastatin Calcium | 14 | $23 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Niles
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.